Trials / Completed
CompletedNCT02937701
Study to Assess if ABP710 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis Compared to Infliximab
A Randomized, Double-Blind Phase 3 Study to Assess the Efficacy and Safety of ABP 710 Compared to Infliximab in Subjects With Moderate to Severe Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 558 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study was to compare rheumatoid arthritis symptom improvement in participants who were given ABP 710 to those who were given infliximab, 22 weeks after starting treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ABP 710 | Administered by intravenous infusion |
| BIOLOGICAL | Infliximab | Administered by intravenous infusion |
Timeline
- Start date
- 2016-10-10
- Primary completion
- 2018-04-16
- Completion
- 2018-08-13
- First posted
- 2016-10-19
- Last updated
- 2019-08-28
- Results posted
- 2019-08-28
Locations
73 sites across 9 countries: United States, Australia, Bulgaria, Canada, Czechia, Germany, Hungary, Poland, Spain
Source: ClinicalTrials.gov record NCT02937701. Inclusion in this directory is not an endorsement.